UCB's Global Corporate Website
Welcome to UCB in the United States

Categories

Archives

Jan

11

Our Wish in 2024: Renewed Hope for People Living with Chronic Inflammatory Diseases

Read More Share:linkedin| twitter| email

Jan

03

ZILBRYSQ® (zilucoplan) Is Now Commercially Available in the U.S. for the Treatment of Generalized Myasthenia Gravis (gMG) in Adult Patients Who Are Anti-Acetylcholine Receptor (AChR) Antibody Positive

Read More Share:linkedin| twitter| email

Dec

02

UCB presents new data about the real-world experience of FINTEPLA® (fenfluramine) and rare epilepsy syndromes at 2023 American Epilepsy Society (AES) Annual Meeting

Read More Share:linkedin| twitter| email

Dec

01

UCB presents new data advancing patient-focused scientific leadership at American Epilepsy Society Annual Meeting

Read More Share:linkedin| twitter| email

Dec

01

Media Statement on levetiracetam (KEPPRA® and KEPPRA XR®) and DRESS

Read More Share:linkedin| twitter| email

Nov

29

Delivering Meaningful and Accessible Innovation for People Living with Severe Diseases

Read More Share:linkedin| twitter| email

Nov

27

UCB's Commitment to Diversity, Equity, and Inclusion: Partnering at AES for a Better Future

Read More Share:linkedin| twitter| email

Nov

17

Employee Spotlight: Stephen Mayclin’s Impact as a Working for Cures Champion and R&D Advocate

Read More Share:linkedin| twitter| email

Nov

14

UCB Announces U.S. Availability of BIMZELX® for the Treatment of Adults with Moderate-to-Severe Plaque Psoriasis

Read More Share:linkedin| twitter| email

Nov

11

Post Hoc Analysis Showed CIMZIA® (Certolizumab Pegol) Resulted in Meaningful Efficacy for RA Patients with High Levels of Rheumatoid Factor (RF)

Read More Share:linkedin| twitter| email

© 2009 - 2020 UCB, Inc., Atlanta. All rights reserved.
USPR-CORP-0115-00003(2)